识别靶向复发性突变 FGFR3 衍生新抗原的 T 细胞受体

Immunotherapies, including immune checkpoint blockades, play a critically important role in cancer treatments. For immunotherapies, neoantigens, which are generated by somatic mutations in cancer cells, are thought to be good targets due to their tumor specificity. Because neoantigens are unique in individual cancers, it is challenging to develop personalized immunotherapy targeting neoantigens.

In this study, we screened "shared neoantigens", which are specific types of neoantigens derived from mutations observed commonly in a subset of cancer patients. Using exome sequencing data in the Cancer Genome Atlas (TCGA), we predicted shared neoantigen peptides and performed in vitro screening of shared neoantigen-reactive CD8 + T cells using peripheral blood from healthy donors.

We examined the functional activity of neoantigen-specific T cell receptors (TCRs) by generating TCR-engineered T cells. Among the predicted shared neoantigens from TCGA data, we found that the mutated FGFR3 Y373C peptide induced antigen-specific CD8 + T cells from the donor with HLA-A*02:06 via an ELISPOT assay. Subsequently, we obtained FGFR3 Y373C -specific CD8 + T cell clones and identified two different sets of TCRs specifically reactive to FGFR3 Y373C .

We found that the TCR-engineered T cells expressing FGFR3 Y373C -specific TCRs recognized the mutated FGFR3 Y373C peptide but not the corresponding wild-type peptide. These two FGFR3 Y373C -specific TCR-engineered T cells showed cytotoxic activity against mutated FGFR3 Y373C -loaded cells. These results imply the possibility of strategies of immunotherapies targeting shared neoantigens, including cancer vaccines and TCR-engineered T cell therapies.